.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The LIBERTY randomized phase 3b trial evaluated erenumab in people with episodic migraine who had already failed two to four preventive treatments because of inadequate efficacy or tolerability. Participants received erenumab 140 mg or placebo for 12 weeks. A clinically important proportion of previously difficult-to-treat patients achieved at least a 50% reduction in monthly migraine days, and the treatment was superior to placebo on several patient-reported outcomes. The trial is significant because many earlier preventive studies enrolled patients without the same degree of treatment failure. LIBERTY therefore supports CGRP-pathway therapy as an option for patients whose migraine remains frequent despite conventional preventive approaches. For HCPs, the practical implication is that a history of preventive failure does not mean that meaningful improvement is unattainable. Treatment choice should still consider comorbidity, reproductive issues, medication overuse and patient preference. The study also illustrates the value of trials that reflect treatment-refractory clinical populations rather than only newly diagnosed patients.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The LIBERTY randomized phase 3b trial evaluated erenumab in people with episodic migraine who had already failed two to four preventive treatments because of inadequate efficacy or tolerability. Participants received erenumab 140 mg or placebo for 12 weeks. A clinically important proportion of previously difficult-to-treat patients achieved at least a 50% reduction in monthly migraine days, and the treatment was superior to placebo on several patient-reported outcomes. The trial is significant because many earlier preventive studies enrolled patients without the same degree of treatment failure. LIBERTY therefore supports CGRP-pathway therapy as an option for patients whose migraine remains frequent despite conventional preventive approaches. For HCPs, the practical implication is that a history of preventive failure does not mean that meaningful improvement is unattainable. Treatment choice should still consider comorbidity, reproductive issues, medication overuse and patient preference. The study also illustrates the value of trials that reflect treatment-refractory clinical populations rather than only newly diagnosed patients.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
